Important clinical research progress in lung cancer in 2022

Chunxia SU; Caicun ZHOU

doi:10.19401/j.cnki.1007-3639.2023.03.004

您当前的位置：

首页 >

文章列表页 >

Important clinical research progress in lung cancer in 2022

Specialists' Commentary | 更新时间：2025-12-31

- Important clinical research progress in lung cancer in 2022
- China Oncology Vol. 33, Issue 3, Pages: 218-227(2023)
- 作者机构：
  
  同济大学附属上海市肺科医院肿瘤科，上海 200433
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2023.03.004
  CLC： R734.2
- Received：18 January 2023，
  
  Revised：2023-03-02，
  
  Published：30 March 2023
- 稿件说明：
移动端阅览
Chunxia SU, Caicun ZHOU. Important clinical research progress in lung cancer in 2022[J]. China Oncology, 2023, 33(3): 218-227.
DOI：

Chunxia SU, Caicun ZHOU. Important clinical research progress in lung cancer in 2022[J]. China Oncology, 2023, 33(3): 218-227. DOI： 10.19401/j.cnki.1007-3639.2023.03.004.

摘要

肺癌仍然是中国发病率和死亡人数最高的恶性肿瘤，其中，非小细胞肺癌（non-small cell lung cancer，NSCLC）约占80%以上。围手术期NSCLC辅助免疫治疗和新辅助免疫治疗相关临床研究推陈出新。靶向治疗方面，罕见及难治性肺癌靶点探索和药物研发持续推进，抗体药物偶联物的研发方兴未艾，有望开辟肺癌诊疗新途径。NSCLC诊疗逐渐步入精准化、规范化时代。在晚期NSCLC患者免疫治疗方面，免疫联合新方案有望进一步提高疗效。本文回顾2022年度NSCLC治疗领域的临床进展，阐述现阶段面临的问题和挑战，并探讨未来发展方向。

Abstract

Lung cancer remains the malignant tumor with the highest morbidity and mortality in China

among which non-small cell lung cancer (NSCLC) accounts for more than 80%. Clinical studies related to adjuvant immunotherapy and neoadjuvant immunotherapy in perioperative NSCLC have been updated. In terms of targeted therapy

the research and development of drugs for rare and difficult-to-treat targets continues to be hot

and the research and development of antibody-drug conjugate gradually becomes hot

which is expected to open a new track for the diagnosis and treatment of lung cancer. Rare target diagnosis and treatment of NSCLC has gradually entered an era of precision and standardization. In terms of immunotherapy for patients with advanced NSCLC

the new regimen of combined immunotherapy is expected to further improve the efficacy. This review

with the focus on advanced NSCLC

summarized the development of NSCLC

discussed current problems and challenges

and proposed prospects on future directions.

关键词

Keywords

references

WAKELEE H , ALTORKI N , FELIP E , et al . PL03.09 IMpower010: overall survival interim analysis of a phase Ⅲ study of atezolizumab vs best supportive care in resected NSCLC [J ] . J Thorac Oncol , 2022 , 17 ( 9 ): S2 .

O’BRIEN M , PAZ-ARES L , MARREAUD S , et al . Pembrolizumab versus placebo as adjuvant therapy for completely resected stage ⅠB-ⅢA non-small cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial [J ] . Lancet Oncol , 2022 , 23 ( 10 ): 1274 - 1286 . DOI: 10.1016/S1470-2045(22)00518-6 http://doi.org/10.1016/S1470-2045(22)00518-6 https://linkinghub.elsevier.com/retrieve/pii/S1470204522005186 https://linkinghub.elsevier.com/retrieve/pii/S1470204522005186

PAZ-ARES L , O’BRIEN M E R , MAUER M , et al . Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: randomized, triple-blind, phase Ⅲ EORTC-1416-LCG/ETOP 8-15-PEARLS/KEYNOTE-091 study [J ] . Ann Oncol , 2022 , 33 ( 4 ): 451 - 453 . DOI: 10.1016/j.annonc.2022.02.224 http://doi.org/10.1016/j.annonc.2022.02.224 https://linkinghub.elsevier.com/retrieve/pii/S0923753422003404 https://linkinghub.elsevier.com/retrieve/pii/S0923753422003404

PASSARO A . Invited Discussant 1529MO, 930MO and 933MO [EB/OL ] . (2022-09-12)[2023-02-02 ] . https://oncologypro.esmo.org/meeting-resources/esmo-congress/invited-discussant-1529mo-930mo-and-933mo. https://oncologypro.esmo.org/meeting-resources/esmo-congress/invited-discussant-1529mo-930mo-and-933mo https://oncologypro.esmo.org/meeting-resources/esmo-congress/invited-discussant-1529mo-930mo-and-933mo

PROVENCIO M , SERNA R , NADAL E , et al . PL03.12 progression free survival and overall survival in NADIM Ⅱ study [J ] . J Thorac Oncol , 2022 , 17 ( 9 ): S2 - S3 .

TSUBOI M , WU Y L , GROHE C , et al . Osimertinib as adjuvant therapy in patients (pts) with resected EGFR -mutated ( EGFR m) stage ⅠB-ⅢA non-small cell lung cancer (NSCLC): updated results from ADAURA [J ] . Ann Oncol , 2022 , 33 : S1413 - S1414 .

YUE D S , XU S D , WANG Q , et al . Updated overall survival and exploratory analysis from randomized, phase Ⅱ EVAN study of erlotinib versus vinorelbine plus cisplatin adjuvant therapy in stage ⅢA epidermal growth factor receptor + non-small cell lung cancer [J ] . J Clin Oncol , 2022 , 40 ( 34 ): 3912 - 3917 . DOI: 10.1200/JCO.22.00428 http://doi.org/10.1200/JCO.22.00428 https://ascopubs.org/doi/10.1200/JCO.22.00428 https://ascopubs.org/doi/10.1200/JCO.22.00428

ZHONG W Z , CHEN K N , CHEN C , et al . Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage ⅢA-N2 EGFR -mutant non-small cell lung cancer (EMERGING-CTONG 1103): a randomized phase Ⅱ study [J ] . J Clin Oncol , 2019 , 37 ( 25 ): 2235 - 2245 .

LYU C , FANG W , JIAO W , et al . Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage Ⅱ-ⅢB lung adenocarcinoma (NEOS): updated results [J ] . Ann Oncol , 2022 , 33 : S71 - S72 .

TSUBOI M , WEDER W , ESCRIU C , et al . Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR -mutated resectable non-small cell lung cancer: NeoADAURA [J ] . Future Oncol , 2021 , 17 ( 31 ): 4045 - 4055 . DOI: 10.2217/fon-2021-0549 http://doi.org/10.2217/fon-2021-0549 https://www.futuremedicine.com/doi/10.2217/fon-2021-0549 https://www.futuremedicine.com/doi/10.2217/fon-2021-0549

FORDE P M , SPICER J , LU S , et al . Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer [J ] . N Engl J Med , 2022 , 386 ( 21 ): 1973 - 1985 . DOI: 10.1056/NEJMoa2202170 http://doi.org/10.1056/NEJMoa2202170 http://www.nejm.org/doi/10.1056/NEJMoa2202170 http://www.nejm.org/doi/10.1056/NEJMoa2202170

SHI Y K , CHEN G , WANG X , et al . Furmonertinib versus gefitinib in treatment-naïve EGFR mutated non-small cell lung cancer: a randomized, double-blind, multi-center, phase Ⅲ study (FURLONG) [J ] . Ann Oncol , 2022 , 33 : S27 .

YUANKAI SHI, MD , et al . Central nervous system efficacy of furmonertinib (AST2818) versus gefitinib as first-line treatment for EGFR -mutated NSCLC: results from the FURLONG study [J ] . J Thorac Oncol , 2022 , 17 ( 11 ): 1297 - 1305 . DOI: 10.1016/j.jtho.2022.07.1143 http://doi.org/10.1016/j.jtho.2022.07.1143 https://linkinghub.elsevier.com/retrieve/pii/S1556086422014964 https://linkinghub.elsevier.com/retrieve/pii/S1556086422014964

GOLDMAN J , HUANG H K T , CUMMINGS A , et al . MA07.05 phase 1b/2 study of combined HER inhibition in refractory EGFR -mutated metastatic non-small cell lung cancer (NSCLC) [J ] . J Thorac Oncol , 2022 , 17 ( 9 ): S68 - S69 .

ALEXANDRA YU H , TAN D S W , SMIT E F , et al . Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (ins20) [J ] . J Clin Oncol , 2022 , 40 ( 16_suppl ): 9007 . DOI: 10.1200/JCO.2022.40.16_suppl.9007 http://doi.org/10.1200/JCO.2022.40.16_suppl.9007 https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.9007 https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.9007

16 ZHOU C C , RAMALINGAM S S , KIM T M , et al . Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1/2 open-label nonrandomized clinical trial [J ] . JAMA Oncol , 2021 , 7 ( 12 ): e214761.

WANG M , YANG J C H , MITCHELL P , et al . Sunvozertinib for NSCLC patients with EGFR exon 20 insertion mutations: preliminary analysis of WU-KONG6, the first pivotal study [J ] . Ann Oncol , 2022 , 33 : S1003 - S1004 .

ZHOU Q , LI J , WANG J , et al . EP08.02-063 SANOVO: a phase 3 study of savolitinib or placebo in combination with osimertinib in patients with EGFR -mutant and MET overexpressed NSCLC [J ] . J Thorac Oncol , 2022 , 17 ( 9 ): S429 .

SWAIN S M , SHASTRY M , HAMILTON E . Targeting HER2-positive breast cancer: advances and future directions [J ] . Nat Rev Drug Discov , 2023 , 22 ( 2 ): 101 - 126 . DOI: 10.1038/s41573-022-00579-0 http://doi.org/10.1038/s41573-022-00579-0

GOLDMAN J W , HORINOUCHI H , CHO B C , et al . Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR -mutated non-small cell lung cancer (NSCLC) [J ] . J Clin Oncol , 2022 , 40 ( 16_suppl ): 9013 . DOI: 10.1200/JCO.2022.40.16_suppl.9013 http://doi.org/10.1200/JCO.2022.40.16_suppl.9013 https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.9013 https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.9013

LI B , SMIT E F , GOTO Y , et al . Primary data from DESTINY-Lung01: a phase 2 trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER 2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC) [C ] . ESMO Congress , 2021 .

LI B T , SMIT E F , GOTO Y , et al . Trastuzumab deruxtecan in HER 2-mutant non-small cell lung cancer [J ] . N Engl J Med , 2022 , 386 ( 3 ): 241 - 251 . DOI: 10.1056/NEJMoa2112431 http://doi.org/10.1056/NEJMoa2112431 http://www.nejm.org/doi/10.1056/NEJMoa2112431 http://www.nejm.org/doi/10.1056/NEJMoa2112431

FDA . FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER 2-mutant non-small cell lung cancer [EB/OL ] . (2022-08-16)[2023-02-02 ] . https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung

ROMÁN M , BARAIBAR I , LÓPEZ I , et al . KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target [J ] . Mol Cancer , 2018 , 17 ( 1 ): 33 . DOI: 10.1186/s12943-018-0789-x http://doi.org/10.1186/s12943-018-0789-x

RECK M , CARBONE D P , GARASSINO M , et al . Targeting KRAS in non-small cell lung cancer: recent progress and new approaches [J ] . Ann Oncol , 2021 , 32 ( 9 ): 1101 - 1110 . DOI: 10.1016/j.annonc.2021.06.001 http://doi.org/10.1016/j.annonc.2021.06.001 https://linkinghub.elsevier.com/retrieve/pii/S0923753421020457 https://linkinghub.elsevier.com/retrieve/pii/S0923753421020457

JÄNNE P A , RIELY G J , GADGEEL S M , et al . Adagrasib in non-small cell lung cancer harboring a KRAS G12C mutation [J ] . N Engl J Med , 2022 , 387 ( 2 ): 120 - 131 . DOI: 10.1056/NEJMoa2204619 http://doi.org/10.1056/NEJMoa2204619 http://www.nejm.org/doi/10.1056/NEJMoa2204619 http://www.nejm.org/doi/10.1056/NEJMoa2204619

SABARI J K , VELCHETI V , SHIMIZU K , et al . Activity of adagrasib (MRTX849) in brain metastases: preclinical models and clinical data from patients with KRAS G12C-mutant non-small cell lung cancer [J ] . Clin Cancer Res , 2022 , 28 ( 15 ): 3318 - 3328 . DOI: 10.1158/1078-0432.CCR-22-0383 http://doi.org/10.1158/1078-0432.CCR-22-0383 https://aacrjournals.org/clincancerres/article/28/15/3318/707087/Activity-of-Adagrasib-MRTX849-in-Brain-Metastases https://aacrjournals.org/clincancerres/article/28/15/3318/707087/Activity-of-Adagrasib-MRTX849-in-Brain-Metastases

FALCHOOK G , LI B T , MARRONE K A , et al . OA03.03 sotorasib in combin ation with RMC-4630, a SHP2 inhibitor, in KRAS p.G12C-mutated NSCLC and other solid tumors [J ] . J Thorac Oncol , 2022 , 17 ( 9 ): S8 .

ZHOU C , LU Y , KIM S W . Alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve advanced ALK + non-small cell lung cancer (NSCLC): 5-year update from the phase Ⅲ ALESIA study [J ] . Ann Oncol , 2022 , 33 : S1563 .

CAMIDGE D R , DZIADZIUSZKO R , PETERS S , et al . Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase Ⅲ ALEX study [J ] . J Thorac Oncol , 2019 , 14 ( 7 ): 1233 - 1243 . DOI: 10.1016/j.jtho.2019.03.007 http://doi.org/10.1016/j.jtho.2019.03.007 https://linkinghub.elsevier.com/retrieve/pii/S1556086419302102 https://linkinghub.elsevier.com/retrieve/pii/S1556086419302102

ZHANG L , FANG W , MIN J , et al . Envonalkib vs crizotinib in treatment-naïve advanced ALK-positive NSCLC: a randomized, multicenter, phase Ⅲ trial [J ] . Ann Oncol , 2022 , 33 : S1564 - S1565 .

LEE S M , SCHULZ C , PRABHASH K , et al . IPSOS: Results from a phase Ⅲ study of first-line (1L) atezolizumab (atezo) vs sing le-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen [J ] . Ann Oncol , 2022 , 33 : S1418 - S1419 .

GARASSINO M C , GADGEEL S M , SPERANZA G , et al . KEYNOTE-189 5-year update: first-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC [J ] . Ann Oncol , 2022 , 33 : S992 - S993 .

NOVELLO S , KOWALSKI D M , LUFT A , et al . Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer: 5-year update of the phase Ⅲ KEYNOTE-407 study [J ] . J Clin Oncol , 2023 . [Online ahead of print ]

JOHNSON M , CHO B C , LUFT A , et al . Durvalumab (D)±tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y) [J ] . Ann Oncol , 2022 , 33 : S1424 - S1425 .

RECKAMP K L , REDMAN M W , DRAGNEV K H , et al . Phase Ⅱ randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small cell lung cancer previously treated with immunotherapy-lung-MAP S1800A [J ] . J Clin Oncol , 2022 , 40 ( 21 ): 2295 - 2306 . DOI: 10.1200/JCO.22.00912 http://doi.org/10.1200/JCO.22.00912 https://ascopubs.org/doi/10.1200/JCO.22.00912 https://ascopubs.org/doi/10.1200/JCO.22.00912

PROF , SHUN , LU , et al . Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR -mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial [J ] . Lancet Oncol , 2022 , 23 ( 9 ): 1167 - 1179 . DOI: 10.1016/S1470-2045(22)00382-5 http://doi.org/10.1016/S1470-2045(22)00382-5 https://linkinghub.elsevier.com/retrieve/pii/S1470204522003825 https://linkinghub.elsevier.com/retrieve/pii/S1470204522003825

LEVY B , PAZ-ARES L , RIXE O , et al . MA13.07 TROPION-Lung02: initial results for datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy in advanced NSCLC [J ] . J Thorac Oncol , 2022 , 17 ( 9 ): S91 .

RECKAMP K L , REDMAN M W , DRAGNEV K H , et al . Overall survival from a phase Ⅱ randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with immunotherapy: lung-MAP nonmatched substudy S1800A [J ] . J Clin Oncol , 2022 , 40 ( suppl 16 ): 9004 . DOI: 10.1200/JCO.2022.40.16_suppl.9004 http://doi.org/10.1200/JCO.2022.40.16_suppl.9004 https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.9004 https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.9004

Views

3442

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Targeted therapy and immunotherapy combined with chemotherapy bring effective response to AFP positive colon cancer patients: a case report and literature review

Research status and progress of third-line treatment for metastatic colorectal cancer

Effectiveness and safety analysis of camrelizumab combined with chemotherapy and targeted therapy in patients with recurrent, metastatic, and treatment-naive advanced cervical cancer: a retrospective cohort study

Research status and prospects of treatment for malignant pleural mesothelioma

Application and prospect of targeted therapy and immunotherapy in radioiodine-refractory differentiated thyroid cancer

Related Author

LIU Miao

LI Jinze

WU Chensi

ZHANG Fengbin

GAO Hongsheng

ZHANG Ruixing

Jingyu LIU

Tong YIN

Related Institution

Department of Gastroenterology, the Fourth Hospital of Hebei Medical University

Department of Pathology, the Fourth Hospital of Hebei Medical University

Department of Oncology, The First Affiliated Hospital of Naval Medical University

Department of Surgical Oncology, Minhang Branch, Fudan University Shanghai Cancer Center

Department of Pharmacy, Minhang Branch, Fudan University Shanghai Cancer Center

AI问答

⁰